Published in Brain Res Bull on June 01, 1986
Oxidative stress and mitochondrial dysfunction in Alzheimer's disease. Biochim Biophys Acta (2013) 1.29
Down's syndrome and Alzheimer's disease: dendritic spine counts in the hippocampus. Acta Neuropathol (1990) 1.23
Trisomy 21 and the brain. J Neuropathol Exp Neurol (2004) 1.11
DYRK1A enhances the mitogen-activated protein kinase cascade in PC12 cells by forming a complex with Ras, B-Raf, and MEK1. Mol Biol Cell (2005) 1.10
Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome. Behav Brain Res (2010) 1.09
Transient expression of Mnb/Dyrk1a couples cell cycle exit and differentiation of neuronal precursors by inducing p27KIP1 expression and suppressing NOTCH signaling. Development (2011) 1.08
Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities. Neural Plast (2012) 1.00
The Down syndrome critical region regulates retinogeniculate refinement. J Neurosci (2011) 1.00
Neurological phenotypes for Down syndrome across the life span. Prog Brain Res (2012) 0.98
BACE2 expression increases in human neurodegenerative disease. Am J Pathol (2011) 0.95
Neuroanatomical localization and quantification of amyloid precursor protein mRNA by in situ hybridization in the brains of normal, aneuploid, and lesioned mice. Proc Natl Acad Sci U S A (1988) 0.91
A unique downregulation of h2-calponin gene expression in Down syndrome: a possible attenuation mechanism for fetal survival by methylation at the CpG island in the trisomic chromosome 21. Mol Cell Biol (1997) 0.90
Diminished serotonin uptake in platelets of transgenic mice with increased Cu/Zn-superoxide dismutase activity. EMBO J (1989) 0.84
Sex differences in the cholinergic basal forebrain in the Ts65Dn mouse model of Down syndrome and Alzheimer's disease. Brain Pathol (2013) 0.84
The mitochondrial epigenome: a role in Alzheimer's disease? Epigenomics (2014) 0.83
N-butylidenephthalide attenuates Alzheimer's disease-like cytopathy in Down syndrome induced pluripotent stem cell-derived neurons. Sci Rep (2015) 0.82
Nerve growth factor corrects developmental impairments of basal forebrain cholinergic neurons in the trisomy 16 mouse. Proc Natl Acad Sci U S A (1991) 0.81
Sensitive pupil response of early-onset alzheimer's patients to a dilute mixture of cholinergic antagonist and α-Adrenergic stimulant. Environ Health Prev Med (1999) 0.77
The GABAergic Hypothesis for Cognitive Disabilities in Down Syndrome. Front Cell Neurosci (2017) 0.75
Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev (1998) 12.48
Unintended changes in cognition, mood, and behavior arising from cell-based interventions for neurological conditions: ethical challenges. Am J Bioeth (2009) 6.13
Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science (1982) 5.63
Derivation of pluripotent stem cells from cultured human primordial germ cells. Proc Natl Acad Sci U S A (1998) 4.92
Alzheimer's disease: a disorder of cortical cholinergic innervation. Science (1983) 4.40
Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet (1995) 3.74
Neurology and psychiatry: closing the great divide. Neurology (2000) 3.68
Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science (1989) 3.47
The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry (2001) 3.20
The glutamatergic basis of human alcoholism. Am J Psychiatry (1995) 3.20
Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol (1981) 3.18
Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress. Neuron (1989) 3.06
Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol (1990) 2.66
Oxidative stress in neurodegenerative diseases. Annu Rev Pharmacol Toxicol (1996) 2.56
A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry (1999) 2.44
D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry (1998) 2.36
Polycythemia in transgenic mice expressing the human erythropoietin gene. Proc Natl Acad Sci U S A (1989) 2.27
Cell-type-specific and hypoxia-inducible expression of the human erythropoietin gene in transgenic mice. Proc Natl Acad Sci U S A (1991) 2.09
Catecholamine uptake by synaptosomes from rat brain. Structure-activity relationships of drugs with differential effects on dopamine and norepinephrine neurons. Mol Pharmacol (1971) 2.08
Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature (1976) 2.08
Regional differences in H3-norepinephrine and H3-dopamine uptake into rat brain homogenates. J Pharmacol Exp Ther (1969) 1.99
Human erythropoietin gene expression in transgenic mice: multiple transcription initiation sites and cis-acting regulatory elements. Mol Cell Biol (1990) 1.88
Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior. Mol Psychiatry (2008) 1.88
Immature cortical neurons are uniquely sensitive to glutamate toxicity by inhibition of cystine uptake. FASEB J (1990) 1.86
Antiparkinsonian drugs: inhibition of dopamine uptake in the corpus striatum as a possible mechanism of action. Science (1969) 1.81
Dopaminergic dsyfunction in Tourette syndrome. Ann Neurol (1982) 1.79
Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience (1991) 1.78
Clonal origins of somites and their muscle derivatives: evidence from allophenic mice. Dev Biol (1972) 1.77
Glutamic acid: selective depletion by viral induced granule cell loss in hamster cerebellum. Brain Res (1974) 1.77
Introduction and expression of the 400 kilobase amyloid precursor protein gene in transgenic mice [corrected]. Nat Genet (1993) 1.74
The role of glutamatergic neurotransmission in the pathophysiology of alcoholism. Annu Rev Med (1998) 1.72
Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry (1995) 1.71
Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc Natl Acad Sci U S A (1998) 1.71
Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci U S A (1996) 1.70
Human embryonic germ cell derivatives express a broad range of developmentally distinct markers and proliferate extensively in vitro. Proc Natl Acad Sci U S A (2001) 1.67
Pilot studies of telemedicine for patients with obsessive-compulsive disorder. Am J Psychiatry (1995) 1.66
Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain. J Biol Chem (1987) 1.64
Cell-based interventions for neurologic conditions: ethical challenges for early human trials. Neurology (2008) 1.57
Catecholamines in fetal and newborn rat brain. J Neurochem (1973) 1.55
Tyrosine hydroxylase in rat brain--cofactor requirements, regional and subcellular distribution. Biochem Pharmacol (1972) 1.49
N-acetylaspartate in neuropsychiatric disorders. Prog Neurobiol (1995) 1.47
Catecholamine uptake by synaptosomes in homogenates of rat brain: stereospecificity in different areas. J Pharmacol Exp Ther (1969) 1.43
Hydroxychloroquine retinopathy. Ophthalmology (2001) 1.42
Goldenhar's syndrome. Arch Ophthalmol (1991) 1.40
Neuroleptic malignant syndrome: life-threatening complication of neuroleptic treatment in adolescents with affective disorder. Pediatrics (1991) 1.40
Peripheral-type benzodiazepine receptors: autoradiographic localization in whole-body sections of neonatal rats. J Pharmacol Exp Ther (1985) 1.29
Sex, strain, and species differences affect recombination across an evolutionarily conserved segment of mouse chromosome 16. Genomics (1990) 1.28
Evidence for a cholinergic projection to neocortex from neurons in basal forebrain. Proc Natl Acad Sci U S A (1979) 1.27
Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res (1986) 1.26
Contact-mediated myogenesis and increased acetylcholinesterase activity in primary cultures of mouse teratocarcinoma cells. Proc Natl Acad Sci U S A (1974) 1.26
Serine racemase deletion disrupts memory for order and alters cortical dendritic morphology. Genes Brain Behav (2010) 1.25
In situ injection of kainic acid: a new method for selectively lesioning neural cell bodies while sparing axons of passage. J Comp Neurol (1978) 1.25
Expression of NF-L in both neuronal and nonneuronal cells of transgenic mice: increased neurofilament density in axons without affecting caliber. J Cell Biol (1990) 1.24
Neurotoxic action of kainic acid. J Neurochem (1983) 1.24
Mouse molecular cytogenetic resource: 157 BACs link the chromosomal and genetic maps. Genome Res (1999) 1.22
Specific binding of [3H]kainic acid to receptor sites in rat brain. Mol Pharmacol (1979) 1.21
Histological and neurochemical effects of fetal treatment with methylazoxymethanol on rat neocortex in adulthood. Brain Res (1979) 1.21
Keratoconus and eye rubbing. Am J Ophthalmol (1984) 1.20
Tissue preferential expression of the hepatitis B virus (HBV) surface antigen gene in two lines of HBV transgenic mice. J Virol (1988) 1.19
The regional vulnerability to hypoglycemia-induced neurotoxicity in organotypic hippocampal culture: protection by early tetrodotoxin or delayed MK-801. J Neurosci (1992) 1.19
Increased glutamatergic neurotransmission and oxidative stress after alcohol withdrawal. Am J Psychiatry (1998) 1.19
The role of brain dopamine in behavioral regulation and the actions of psychotropic drugs. Am J Psychiatry (1970) 1.18
Cortical degeneration with swollen chromatolytic neurons: its relationship to Pick's disease. J Neuropathol Exp Neurol (1986) 1.15
Psychotropic drug use in very young children. JAMA (2000) 1.15
Kainic acid stimulates excitatory amino acid neurotransmitter release at presynaptic receptors. Nature (1982) 1.15
Platelet serotonin, a possible marker for familial autism. J Autism Dev Disord (1991) 1.14
Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry (1995) 1.13
Primary degenerative dementia without Alzheimer pathology. Can J Neurol Sci (1986) 1.13
Association of postoperative delirium with raised serum levels of anticholinergic drugs. Lancet (1981) 1.13
Glutamate neurotoxicity and the inhibition of protein synthesis in the hippocampal slice. J Neurochem (1991) 1.11
Altered metabolism of familial Alzheimer's disease-linked amyloid precursor protein variants in yeast artificial chromosome transgenic mice. Hum Mol Genet (1997) 1.10
N-acetyl-aspartyl-glutamate: regional levels in rat brain and the effects of brain lesions as determined by a new HPLC method. J Neurochem (1984) 1.10
Immunocytochemical localization of the N-acetyl-aspartyl-glutamate (NAAG) hydrolyzing enzyme N-acetylated alpha-linked acidic dipeptidase (NAALADase). J Comp Neurol (1992) 1.09
Topographic analysis of the innervation of the rat neocortex and hippocampus by the basal forebrain cholinergic system. J Comp Neurol (1983) 1.09
Astrocytosis and axonal proliferation in the hippocampus of S100b transgenic mice. Proc Natl Acad Sci U S A (1994) 1.09
Selective destruction of neurons by a transmitter agonist. Science (1977) 1.08
Avoidance conditioning in different strains of rats: neurochemical correlates. Psychopharmacologia (1973) 1.08
Growth retardation and neonatal lethality in mice with a homozygous deletion in the C-terminal domain of RNA polymerase II. Mol Gen Genet (1999) 1.08
Enhanced NAD(P)H:quinone reductase activity prevents glutamate toxicity produced by oxidative stress. J Neurochem (1991) 1.08
Antioxidants protect against glutamate-induced cytotoxicity in a neuronal cell line. J Pharmacol Exp Ther (1989) 1.07
Intracellular modulation of NMDA receptor function by antipsychotic drugs. J Neurosci (2000) 1.07
Glutamate carboxypeptidase II is expressed by astrocytes in the adult rat nervous system. J Comp Neurol (1999) 1.07
Neurochemical aspects of the ontogenesis of cholinergic neurons in the rat brain. Brain Res (1976) 1.06
Impairments in learning and memory accompanied by neurodegeneration in mice transgenic for the carboxyl-terminus of the amyloid precursor protein. Brain Res Mol Brain Res (1999) 1.06
Serum levels of anticholinergic drugs in treatment of acute extrapyramidal side effects. Arch Gen Psychiatry (1980) 1.06
Folylpoly-gamma-glutamate carboxypeptidase from pig jejunum. Molecular characterization and relation to glutamate carboxypeptidase II. J Biol Chem (1998) 1.06
Neurochemical aspects of the ontogenesis of GABAnergic neurons in the rat brain. Brain Res (1976) 1.05
Genetic basis for a mouse model of Down syndrome. Brain Res Bull (1986) 1.04
Down syndrome, Alzheimer's disease and the trisomy 16 mouse. Trends Neurosci (1988) 1.04
Direct observation of the agonist-specific regional vulnerability to glutamate, NMDA, and kainate neurotoxicity in organotypic hippocampal cultures. Exp Neurol (1991) 1.04
Glutamate and related acidic excitatory neurotransmitters: from basic science to clinical application. FASEB J (1987) 1.04
Neocortical cholinergic innervation: a description of extrinsic and intrinsic components in the rat. Exp Brain Res (1981) 1.04
The distribution and orientation of noradrenergic fibers in neocortex of the rat: an immunofluorescence study. J Comp Neurol (1978) 1.04
Dopamine receptors localised on cerebral cortical afferents to rat corpus striatum. Nature (1978) 1.03
Ontogenetic development of kainate neurotoxicity: correlates with glutamatergic innervation. Proc Natl Acad Sci U S A (1978) 1.03
Self-injurious behavior: gene-brain-behavior relationships. Ment Retard Dev Disabil Res Rev (2001) 1.03